Singapore’s Tikva targets solid cancer barrier with US$8M Series A
Summary
For years, cell therapy has carried one of oncology’s most striking contradictions. It has changed the outlook for some blood cancer patients, yet has struggled to make the same impact in solid tumours, which account for the vast majority of cancer cases worldwide. Singapore-based Tikva Allocell is trying to push through that wall with a […] The post Singapore’s Tikva targets solid cancer barrier with US$8M Series A appeared first on e27 .
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For Singapore, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketSingapore
- ImpactMedium (52/100)
- SignalFunding